2 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
Follow Soft-tissue Sarcoma: new trials by email Literature Review of Soft-tissue Sarcoma trials Research Report on Soft-tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut BergoniƩ | 747 | 2018-05-04 | 2023-03-03 |
| A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide - Solid Tumors, Soft-tissue Sarcoma | Phase 1 / Phase 2 | Unknown | Institut BergoniƩ | 197 | 2015-09-18 | 2022-02-02 |
Sarcoma (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1) · Tertiary Lymphoid Structures (1) · Thyroid Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Turcot syndrome (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Connective and Soft Tissue (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adenocarcinoma (1) · Adenoma (1) · Biliary Tract Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1)
Clinical Trials, Phase II as Topic (1) · Cyclophosphamide (1) · avelumab (1) · regorafenib (1)
France (2)
PMID 34965951, PMID 34998048, PMID 40204996, PMID 40579407
2014 (1), 2016 (1)